The Role of p53-inducible Sesn1 and Sesn2 genes in lung carcinogenesis

p53诱导的Sesn1和Sesn2基因在肺癌发生中的作用

• 批准号: 8997468
• 负责人: Steven R. Grossman
• 金额: $ 31.64万
• 依托单位: VIRGINIA COMMONWEALTH UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-02-01 至 2018-01-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8997468
• 关键词: Address; Adenocarcinoma; Affect; Autophagocytosis; Cancer Etiology; Cancer Model; Cell Cycle Arrest; Cell Death; Cell Proliferation; Cell Proliferation Regulation; Cell Survival; Cells; Cessation of life; DNA Damage; Depressed mood; Development; Diagnosis; Diagnostic; Disease; Epithelial Cell Proliferation; FRAP1 gene; Gene Family; Genes; Genetic; Goals; Health; Human; K-ras mouse model; KRAS2 gene; Knockout Mice; Knowledge; Link; Lung; Malignant neoplasm of lung; Mediating; Mesenchymal; Metabolism; Mission; Modeling; Mus; Mutagenesis; Mutation; Neoplasm Metastasis; Non-Small-Cell Lung Carcinoma; Outcome; Oxidative Stress; Pathway interactions; Patients; Pharmaceutical Preparations; Phosphotransferases; Property; Protein p53; Proto-Oncogenes; Public Health; Radiation therapy; Reactive Oxygen Species; Regulation; Research; Role; STK11 gene; Signal Pathway; Staging; Stress; Structure of parenchyma of lung; Suppressor Genes; Survival Rate; TP53 gene; Transcriptional Regulation; Tumor Angiogenesis; Tumor Suppression; Tumor Suppressor Genes; Tumor Suppressor Proteins; Work; Xenograft procedure; adenoma; angiogenesis; anticancer treatment; base; cancer cell; cancer initiation; cancer therapy; carcinogenesis; cell growth; design; improved; irradiation; lung carcinogenesis; mTOR Signaling Pathway; mTOR inhibition; mitochondrial dysfunction; mortality; mouse model; mutant; novel; novel strategies; overexpression; oxidative damage; response; trait; tumor; tumor growth

DESCRIPTION (provided by applicant): Around a million people are diagnosed with non-small cell lung cancer (NSCLC) worldwide each year and 85% of them will die during next 5 years. In spite of considerable efforts to improve the diagnostics and efficiency of treatment, the changes in mortality rate for the last couple decades is less than 2%. New effective approaches for anti-cancer therapy are hindered by the lack of knowledge of the mechanisms of lung carcinogenesis and a predictive strategy for efficient treatment. Among the genes dysregulated in NSCLC mutations in p53 and LKB1 are major traits, and their critical effect on lung carcinogenesis is supported by many mouse models. P53 suppresses carcinogenesis through transcriptional regulation of a number of genes, although the critical targets involved in tumor suppression are unknown. The LKB1 kinase phosphorylates and activates AMPK leading to inhibition of mTOR kinase, critical regulator of cell growth, proliferation and metabolism, which i activated in many lung cancers. Strikingly, similar to LKB1 p53 inhibits mTOR through activation of AMPK, although the inter-relation between p53- and LKB1-regulated signaling pathways is not well characterized. Recently we described a novel Sestrin (Sesn) gene family of stress-responsive genes in which expression is regulated in a p53-dependent manner. Sesns inhibit mTOR through AMPK regulation causing inhibition of cell growth and proliferation, activation of autophagy and protection against oxidative damage. Sesn1 and Sesn2 are downregulated in most human lung cancers and this leads to dysregulation of tumor growth and angiogenesis, so the Sesns are potential tumor suppressors and effectors of p53. The objective of the proposed work is to establish the importance of Sesn1 and Sesn2 in suppression of lung carcinogenesis and the outcome of anticancer treatment. To accomplish that we set up the following specific aims: Aim 1: To determine tumor suppressor properties of Sesn1 and Sesn2. We will apply of mouse model of K-ras-induced lung carcinogenesis and study whether inactivation or overexpression of Sesns modulate lung carcinogenesis. We will address the potential mechanisms, which involve regulation of cell proliferation and cell death, oxidative stress, autophagy and metabolism. Aim 2: To study the impact of the AMPK-mTOR pathway in regulation of carcinogenesis by Sesn1/2. We will analyze the role of Sesn1/2 in regulation of the AMPK-mTOR pathway in lung tissue and cancers and study whether the modulation of this pathway affects tumor-suppression function of Sesns. Aim 3: To understand the role of Sesn1/2 in anticancer treatment. We will treat Sesn1/2-deficient and proficient tumors and cancer cells with irradiation and DNA-damaging drugs and determine the impact of Sesn1/2 in tumor growth, cell viability and proliferation. The accomplishment of these goals let us to understand the mechanisms of tumor suppression in lung and design the more advanced approaches to diagnose and treat lung cancers decreasing the enormous death toll.

描述（申请人提供）：全球每年约有100万人被诊断出患有非小细胞肺癌（NSCLC），其中85%将在未来5年内死亡。尽管在改善诊断和治疗效率方面做出了相当大的努力，但过去几十年死亡率的变化不到2%。由于对肺癌发生机制和有效治疗的预测策略缺乏了解，新的有效抗癌治疗方法受到阻碍。 在NSCLC中失调的基因中，p53和LKB 1突变是主要特征，并且它们对肺癌发生的关键作用得到许多小鼠模型的支持。P53通过转录调节许多基因来抑制癌发生，尽管参与肿瘤抑制的关键靶点尚不清楚。LKB 1激酶磷酸化并激活AMPK，导致mTOR激酶的抑制，mTOR激酶是细胞生长、增殖和代谢的关键调节因子，在许多肺癌中被激活。引人注目的是，与LKB 1类似，p53通过激活AMPK抑制mTOR，尽管p53和LKB 1调节的信号通路之间的相互关系尚未得到很好的表征。 最近，我们描述了一个新的应激反应基因Sestrin（Sesn）基因家族，其中表达以p53依赖性方式调节。Sesn通过AMPK调节抑制mTOR，引起细胞生长和增殖的抑制、自噬的激活和对氧化损伤的保护。Sesn 1和Sesn 2在大多数人肺癌中下调，这导致肿瘤生长和血管生成的失调，因此Sesn是p53的潜在肿瘤抑制因子和效应因子。这项工作的目的是确定Sesn 1和Sesn 2在抑制肺癌发生和抗癌治疗结果中的重要性。为了实现这一目标，我们建立了以下具体目标：目标1：确定Sesn 1和Sesn 2的肿瘤抑制特性。我们将应用K-ras诱导的小鼠肺癌模型，研究Sesns的失活或过表达是否参与肺癌的发生。我们将讨论潜在的机制，涉及细胞增殖和细胞死亡，氧化应激，自噬和代谢的调节。 目的2：研究AMPK-mTOR通路在Sesn 1/2调控肿瘤发生中的作用。 我们将分析Sesn 1/2在肺组织和癌症中调节AMPK-mTOR通路的作用，并研究该通路的调节是否影响Sesns的肿瘤抑制功能。 目的3：了解Sesn 1/2在抗肿瘤治疗中的作用。 我们将用辐射和DNA损伤药物治疗Sesn 1/2缺陷和熟练的肿瘤和癌细胞，并确定Sesn 1/2对肿瘤生长，细胞活力和增殖的影响。 这些目标的实现使我们能够更好地了解肺癌的抑制机制，设计更先进的诊断和治疗方法，减少巨大的死亡人数。